MA20150232A1 - Protéines de fusion de l'interleukine-10 et leurs utilisations - Google Patents

Protéines de fusion de l'interleukine-10 et leurs utilisations

Info

Publication number
MA20150232A1
MA20150232A1 MA37793A MA37793A MA20150232A1 MA 20150232 A1 MA20150232 A1 MA 20150232A1 MA 37793 A MA37793 A MA 37793A MA 37793 A MA37793 A MA 37793A MA 20150232 A1 MA20150232 A1 MA 20150232A1
Authority
MA
Morocco
Prior art keywords
interleukin
fusion
proteins
fusion proteins
methods
Prior art date
Application number
MA37793A
Other languages
English (en)
Inventor
Jens Fischer
Lydia Jasmin Duerner
Thomas Emrich
Ralf Hosse
Ekkehard Moessner
Pablo Umana
Daigen Xu
Original Assignee
Roche Glycart Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48917543&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA20150232(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Roche Glycart Ag filed Critical Roche Glycart Ag
Publication of MA20150232A1 publication Critical patent/MA20150232A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5428—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2066—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne en général des protéines de fusion d'anticorps et d'interleukine-10 (il-10). De plus, la présente invention concerne des polynucléotides codant pour de telles protéines de fusion, et des vecteurs et cellules hôtes comprenant de tels polynucléotides. L'invention concerne en outre des procédés de production des protéines de fusion de l'invention et des procédés d'utilisation de celles-ci dans le traitement d'une maladie.
MA37793A 2012-08-08 2013-08-05 Protéines de fusion de l'interleukine-10 et leurs utilisations MA20150232A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12179709 2012-08-08
PCT/EP2013/066342 WO2014023673A1 (fr) 2012-08-08 2013-08-05 Protéines de fusion de l'interleukine-10 et leurs utilisations

Publications (1)

Publication Number Publication Date
MA20150232A1 true MA20150232A1 (fr) 2015-07-31

Family

ID=48917543

Family Applications (1)

Application Number Title Priority Date Filing Date
MA37793A MA20150232A1 (fr) 2012-08-08 2013-08-05 Protéines de fusion de l'interleukine-10 et leurs utilisations

Country Status (23)

Country Link
US (2) US9346872B2 (fr)
EP (1) EP2882774B1 (fr)
JP (3) JP2015530983A (fr)
KR (1) KR20150038012A (fr)
CN (1) CN104540848B (fr)
AR (1) AR092050A1 (fr)
AU (1) AU2013301656A1 (fr)
BR (1) BR112015002085A2 (fr)
CA (1) CA2876285A1 (fr)
CL (1) CL2014003605A1 (fr)
CO (1) CO7151522A2 (fr)
CR (1) CR20140565A (fr)
EA (1) EA201500208A1 (fr)
HK (1) HK1209439A1 (fr)
IL (1) IL236809A0 (fr)
MA (1) MA20150232A1 (fr)
MX (1) MX2015001675A (fr)
PE (1) PE20150645A1 (fr)
PH (1) PH12015500284A1 (fr)
SG (1) SG11201408526SA (fr)
TW (1) TW201418283A (fr)
WO (1) WO2014023673A1 (fr)
ZA (1) ZA201409304B (fr)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2603530T1 (en) 2010-08-13 2018-02-28 Roche Glycart Ag Anti-FAP antibodies and methods of use
HUE055284T2 (hu) 2011-02-10 2021-11-29 Roche Glycart Ag Mutáns interleukin-2 polipeptidek
US9550819B2 (en) 2012-03-27 2017-01-24 Ngm Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
JP6272907B2 (ja) 2013-01-30 2018-01-31 エヌジーエム バイオファーマシューティカルズ インコーポレイテッド 代謝障害の処置における組成物及び使用方法
US9161966B2 (en) 2013-01-30 2015-10-20 Ngm Biopharmaceuticals, Inc. GDF15 mutein polypeptides
UA118028C2 (uk) 2013-04-03 2018-11-12 Рош Глікарт Аг Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування
EP3062889A2 (fr) 2013-11-01 2016-09-07 Spherium Biomed S.L. Corps d'inclusion pour administration transdermique d'agents thérapeutiques et cosmétiques
MX2016010174A (es) * 2014-02-06 2016-11-15 Hoffmann La Roche Proteinas de fusion de interleucina-10 y usos de las mismas.
EP3142691A4 (fr) 2014-05-16 2018-04-11 Baylor Research Institute Méthodes et compositions de traitement de maladies auto-immunes et inflammatoires
JP6704358B2 (ja) 2014-07-30 2020-06-03 エヌジーエム バイオファーマシューティカルズ インコーポレイテッド 代謝障害を治療するための組成物および使用方法
US9920118B2 (en) 2014-10-31 2018-03-20 Ngm Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
HUE049982T2 (hu) 2014-11-14 2020-11-30 Hoffmann La Roche TNF-családba tartozó ligandum-trimert tartalmazó antigénkötõ molekulák
ES2824151T3 (es) 2014-12-19 2021-05-11 Alkermes Inc Proteínas de fusión Fc monocatenarias
JP6996979B2 (ja) 2015-03-31 2022-02-04 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 三量体ｔｎｆファミリーリガンドを含む抗原結合分子
AR106188A1 (es) 2015-10-01 2017-12-20 Hoffmann La Roche Anticuerpos anti-cd19 humano humanizados y métodos de utilización
EP3356403A2 (fr) 2015-10-02 2018-08-08 H. Hoffnabb-La Roche Ag Anticorps bispécifiques spécifiques d'un récepteur de co-stimulation du tnf
US11219645B2 (en) 2015-11-18 2022-01-11 Duke University Tumor infiltrating lymphocytes for treatment of cancer
US10144768B2 (en) * 2015-12-04 2018-12-04 Novartis Ag Antibody cytokine engrafted compositions and methods of use for immunoregulation
CN106349393B (zh) * 2015-12-21 2020-10-30 合肥立方制药股份有限公司 一种增强抗体药物稳定性的结构
JP7021099B2 (ja) 2016-03-31 2022-02-18 エヌジーエム バイオファーマシューティカルス，インコーポレーテッド 結合タンパク質及びその使用方法
EP3474884A4 (fr) 2016-06-22 2020-08-19 Alkermes, Inc. Compositions et méthodes permettant de moduler les propriétés immunostimulantes et anti-inflammatoires de l'il-10
CN112142859A (zh) * 2017-05-22 2020-12-29 杭州博虎生物科技有限公司 一种人白细胞介素10-Fc融合蛋白及其编码基因与应用
JOP20190271A1 (ar) 2017-05-24 2019-11-21 Novartis Ag بروتينات مطعّمة بسيتوكين- الجسم المضاد وطرق الاستخدام للاضطرابات المتعلقة بالمناعة
CA3063983A1 (fr) 2017-05-24 2018-11-29 Novartis Ag Proteines greffees d'anticorps-cytokine et procedes d'utilisation dans le traitement du cancer
CN111132998B (zh) * 2017-09-25 2024-01-30 苏州丁孚靶点生物技术有限公司 用于癌症治疗的方法和组合物
US11987609B2 (en) 2017-09-25 2024-05-21 Dingfu Biotarget Co., Ltd. Proteinaceous heterodimer and use thereof
CN112996805A (zh) 2018-08-30 2021-06-18 Hcw生物科技公司 多链嵌合多肽和其用途
WO2020047473A1 (fr) 2018-08-30 2020-03-05 HCW Biologics, Inc. Polypeptides chimères à chaîne unique et à chaînes multiples et leurs utilisations
AU2019328313A1 (en) 2018-08-30 2021-02-25 HCW Biologics, Inc. Single-chain chimeric polypeptides and uses thereof
TW202033766A (zh) * 2018-11-26 2020-09-16 大陸商江蘇恆瑞醫藥股份有限公司 一種人白細胞介素１０變體及其衍生物
US11084857B2 (en) 2018-12-05 2021-08-10 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Nsp-interleukin-10 proteins and uses thereof
WO2020160244A1 (fr) * 2019-02-01 2020-08-06 Uab Research Foundation Procédés et compositions pour antagonisme de la signalisation induite par l'il10
CN113811549A (zh) 2019-02-21 2021-12-17 Xencor股份有限公司 非靶向和靶向性il-10 fc融合蛋白
KR20210139312A (ko) 2019-03-06 2021-11-22 데카 바이오사이언시즈, 인크. Il-10 변이체 분자, 및 염증 질환 및 종양학의 치료 방법
CN111909276A (zh) * 2019-05-10 2020-11-10 复旦大学 一种融合蛋白及其用途
JP2022536898A (ja) 2019-06-12 2022-08-22 アスクジーン・ファーマ・インコーポレイテッド 新規ｉｌ－１５プロドラッグおよびその使用方法
US11738052B2 (en) 2019-06-21 2023-08-29 HCW Biologics, Inc. Multi-chain chimeric polypeptides and uses thereof
WO2021006605A1 (fr) * 2019-07-08 2021-01-14 주식회사 프로젠 Nouvelle protéine de variant d'il-10 et utilisation de celle-ci
EP3998282A4 (fr) * 2019-07-08 2023-08-09 Progen Co., Ltd. Nouvelle protéine de fusion et son utilisation
WO2021006603A1 (fr) * 2019-07-08 2021-01-14 주식회사 프로젠 Nouvelle composition pharmaceutique pour le traitement de maladies allergiques
CN112625137B (zh) * 2019-10-08 2021-10-08 北京东方百泰生物科技股份有限公司 一种人白细胞介素10-Fc融合蛋白及其医药用途
CN112618698B (zh) * 2019-10-08 2021-10-08 北京东方百泰生物科技股份有限公司 一种人白细胞介素10-Fc融合蛋白的注射制剂
EP4103601A2 (fr) 2020-02-11 2022-12-21 HCW Biologics, Inc. Méthodes de traitement de maladies liées à l'âge et inflammatoires
CA3169243A1 (fr) 2020-02-11 2021-08-19 HCW Biologics, Inc. Methodes d'activation de lymphocytes t regulateurs
JP2023519106A (ja) 2020-02-11 2023-05-10 エイチシーダブリュー バイオロジックス インコーポレイテッド クロマトグラフィー樹脂およびその使用
CN115836087A (zh) 2020-04-29 2023-03-21 Hcw生物科技公司 抗cd26蛋白及其用途
CA3183151A1 (fr) 2020-05-12 2021-11-18 Regeneron Pharmaceuticals, Inc. Nouveaux agonistes d'il10 et leurs procedes d'utilisation
KR20210141406A (ko) * 2020-05-14 2021-11-23 주식회사 프로젠 신규 재조합 융합단백질 및 그의 용도
IL298608A (en) 2020-06-01 2023-01-01 Hcw Biologics Inc Methods for treating disorders related to aging
WO2021247003A1 (fr) 2020-06-01 2021-12-09 HCW Biologics, Inc. Méthodes de traitement de troubles liés au vieillissement
KR20230096959A (ko) 2020-07-20 2023-06-30 데카 바이오사이언시즈, 인크. Il-10을 포함하는 이중 시토카인 융합 단백질
TW202216744A (zh) * 2020-07-20 2022-05-01 美商維埃拉生物股份有限公司 用於治療自體免疫性病症和炎性病症之免疫細胞介素
MA61003A1 (fr) * 2020-12-10 2023-10-31 Biocad Joint Stock Co Immunocytokine pour activer le récepteur il-10ra humain et son utilisation
KR20220099656A (ko) * 2021-01-07 2022-07-14 주식회사 프로젠 신규 il-10 변이체 융합단백질 생산용 세포주 및 그의 용도
WO2022165443A1 (fr) * 2021-02-01 2022-08-04 AskGene Pharma, Inc. Molécules chimériques comprenant un polypeptide agoniste de l'il-10 ou du tgf-bêta
TW202325746A (zh) * 2021-11-02 2023-07-01 大陸商廣東菲鵬製藥股份有限公司 中國廣東省東莞市松山湖園區桃園路1號10棟301室 郵編：523808 Il10單體融合蛋白及其應用
WO2023168363A1 (fr) 2022-03-02 2023-09-07 HCW Biologics, Inc. Méthode de traitement du cancer du pancréas

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7802170A (nl) 1977-04-18 1978-10-20 Hitachi Metals Ltd Sierraad.
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
ES2052027T5 (es) 1988-11-11 2005-04-16 Medical Research Council Clonacion de secuencias de dominio variable de inmunoglobulina.
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
EP1400536A1 (fr) 1991-06-14 2004-03-24 Genentech Inc. Procédé pour fabriquer des anticorps humanisés
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
AU675929B2 (en) 1992-02-06 1997-02-27 Curis, Inc. Biosynthetic binding protein for cancer marker
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
DK1034298T3 (da) 1997-12-05 2012-01-30 Scripps Research Inst Humanisering af murint antistof
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
KR100797667B1 (ko) 1999-10-04 2008-01-23 메디카고 인코포레이티드 외래 유전자의 전사를 조절하는 방법
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
US7432063B2 (en) 2002-02-14 2008-10-07 Kalobios Pharmaceuticals, Inc. Methods for affinity maturation
WO2005097832A2 (fr) 2004-03-31 2005-10-20 Genentech, Inc. Anticorps anti-tgf-$g(b) humanises
PL1737891T3 (pl) 2004-04-13 2013-08-30 Hoffmann La Roche Przeciwciała przeciw selektynie p
EP1919950A1 (fr) 2004-07-15 2008-05-14 Xencor, Inc. Variantes genetiques de fc optimisees
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
EA200802289A1 (ru) * 2006-05-08 2009-04-28 Филоджен Спа Направляемые к мишени антителами цитокины для терапии
ES2807753T3 (es) * 2007-10-30 2021-02-24 Philogen Spa Un antígeno asociado con artritis reumatoide
WO2010005389A1 (fr) 2008-07-11 2010-01-14 Forskarpatent I Syd Ab Protéines conjuguées ou fusionnées à un anticorps spécifique des protéines ldl oxydées
EP2467165B1 (fr) 2009-08-17 2015-01-07 Roche Glycart AG Immunoconjugués ciblés
SI2603530T1 (en) 2010-08-13 2018-02-28 Roche Glycart Ag Anti-FAP antibodies and methods of use
MX354359B (es) 2011-03-29 2018-02-28 Roche Glycart Ag Variantes de fragmento cristalizable (fc) de los anticuerpos.
EA201892619A1 (ru) * 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
MX2016010174A (es) 2014-02-06 2016-11-15 Hoffmann La Roche Proteinas de fusion de interleucina-10 y usos de las mismas.

Also Published As

Publication number Publication date
JP2021087426A (ja) 2021-06-10
CN104540848B (zh) 2019-05-31
SG11201408526SA (en) 2015-03-30
PE20150645A1 (es) 2015-05-11
JP2015530983A (ja) 2015-10-29
EA201500208A1 (ru) 2015-07-30
CR20140565A (es) 2015-02-12
HK1209439A1 (en) 2016-04-01
AU2013301656A1 (en) 2015-01-15
KR20150038012A (ko) 2015-04-08
JP6985232B2 (ja) 2021-12-22
CL2014003605A1 (es) 2015-04-06
CN104540848A (zh) 2015-04-22
BR112015002085A2 (pt) 2017-12-19
US9346872B2 (en) 2016-05-24
US20160340413A1 (en) 2016-11-24
WO2014023673A1 (fr) 2014-02-13
AR092050A1 (es) 2015-03-18
EP2882774B1 (fr) 2018-10-03
CO7151522A2 (es) 2014-12-29
TW201418283A (zh) 2014-05-16
US10040843B2 (en) 2018-08-07
ZA201409304B (en) 2017-09-27
JP2019033755A (ja) 2019-03-07
CA2876285A1 (fr) 2014-02-13
EP2882774A1 (fr) 2015-06-17
PH12015500284A1 (en) 2015-04-27
IL236809A0 (en) 2015-03-31
MX2015001675A (es) 2015-04-10
US20140044674A1 (en) 2014-02-13

Similar Documents

Publication Publication Date Title
MA20150232A1 (fr) Protéines de fusion de l'interleukine-10 et leurs utilisations
MA37894A1 (fr) Protéines de fusion d'interleukine-2 et leurs utilisations
MA38406B1 (fr) Virus de la maladie de newcastle et leurs utilisations
TR201910103T4 (tr) Anti-fcrn antikorları.
MA38308A1 (fr) Molécules de liaison à l'antigène bispécifiques activant des lymphocytes t
MA35130B1 (fr) Composition comprenant de l'aflibercept, de l'acide folinique, du 5-fluoro-uracile (5-fu) et de l'irinocetan (folfiri)
BR112013023006A8 (pt) formulações de suspensões não aquosas de anticorpos de alta concentração e viscosidade reduzida
GB2513768A (en) Complexes of cytomegalovirus proteins
EA201590910A1 (ru) Белки на основе структурного домена фибронектина, связывающие pcsk9
CL2011003122A1 (es) Anticuerpo que se une a la proteina tau fosforilada en la serina 422 (tau ps422), pero no se une a la tau ni al fragmento mcak fosforilado; acido nucleico que lo codifica; metodo de produccion; composicion farmaceutica; y uso util en el tratamiento de una tauopatia, tal como la enfermedad de alzheimer.
UA111340C2 (uk) Антитіло, яке специфічно зв'язується з tnf-альфа людини
MA44922B1 (fr) Anticorps
EA201890172A1 (ru) Тау-связывающие антитела
MA34521B1 (fr) Polypeptides de relaxine modifiés et leurs utilisations
MX2018015914A (es) Anticuerpos frente a los ligandos del receptor b1 de bradicinina.
MA38686A1 (fr) Anticorps anti-acide téichoïque de la paroi cellulaire et conjugués associés
SG10201811186XA (en) Purification of proteins
MA35935B1 (fr) Oligonucléotides pour moduler l'expression de gènes et leurs utilisations
MA39096B1 (fr) Anticorps spécifiques à fcrn
MA40283A (fr) Aptamères spécifiques du récepteur tlr-4 et leurs utilisations
MX357655B (es) Mediador soluble.
EA201491513A1 (ru) Рекомбинантные штаммы escherichia coli
FR2986229B1 (fr) Nouveaux monergols ioniques a base de n2o pour la propulsion spatiale
EA201491724A1 (ru) Антитела, нейтрализующие rsv, mpv и pvm, и их применения
FR2968559B1 (fr) Nouvelles compositions a base d'argile et de beepollen, leur procede de preparation et leurs utilisations en nutrition et en therapeutique